Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.61B P/E - EPS this Y -3.40% Ern Qtrly Grth -
Income -61.68M Forward P/E -19.85 EPS next Y -7.30% 50D Avg Chg 5.00%
Sales 11.28M PEG - EPS past 5Y - 200D Avg Chg 52.00%
Dividend N/A Price/Book 8.18 EPS next 5Y - 52W High Chg -12.00%
Recommedations 1.70 Quick Ratio 9.15 Shares Outstanding 24.08M 52W Low Chg 204.00%
Insider Own 16.50% ROA -22.14% Shares Float 11.37M Beta -0.35
Inst Own 65.90% ROE -57.89% Shares Shorted/Prior 480.18K/428.65K Price 54.60
Gross Margin -244.20% Profit Margin - Avg. Volume 348,626 Target Price 44.67
Oper. Margin -540.96% Earnings Date Aug 3 Volume 79,959 Change -0.58%
Bicycle Therapeutics plc News
11/11/21 Bicycle Therapeutics to Participate in Upcoming Investor Conferences
11/09/21 Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
11/05/21 Shareholders have faith in loss-making Bicycle Therapeutics (NASDAQ:BCYC) as stock climbs 6.0% in past week, taking one-year gain to 200%
11/04/21 Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/04/21 Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
11/02/21 Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer
10/26/21 Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
10/18/21 Analysts Just Increased Price Targets of These 10 Stocks
10/18/21 Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/12/21 Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
10/12/21 Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares
10/07/21 Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
10/04/21 Bicycle Therapeutics PLC Sponsored ADR (BCYC) Surges 7%: Is This an Indication of Further Gains?
09/30/21 Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
08/07/21 Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Just Cut Their EPS Forecasts Substantially
08/05/21 Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
07/29/21 Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View
07/28/21 Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View
07/23/21 Bicycle Therapeutics PLC Sponsored ADR (BCYC) Is a Great Choice for "Trend" Investors, Here's Why

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Chatroom

User Image biostocks33 Posted - 19 hours ago

$BCYC solid day for this added more

User Image BidaskBot Posted - 3 days ago

BicycleTherapeutics $BCYC BidaskScore is Downgraded to Held https://bidaskclub.com/news/company/2021-11-22/BCYC

User Image quantcha Posted - 4 days ago

Covered Call Alert: BICYCLE THERAPEUTICS LTD $BCYC returning up to 24.07% through 18-Mar-2022 https://wp.me/p5bLGB-eWQT

User Image T8skmod Posted - 4 days ago

$BCYC Twits Stats Today's Change 15% + 🚀 https://t8sk.com/BCYC

User Image tickeron Posted - 5 days ago

Oh wow this is big! $BCYC in Downtrend: its price may drop because broke its higher Bollinger Band on November 8, 2021. View odds for this and other indicators: https://srnk.us/go/3175909

User Image Tickstocks Posted - 6 days ago

$BCYC Twits Stats Today's Change 15% + 🚀 https://t8sk.com/BCYC

User Image Fox_Technicals Posted - 1 week ago

$BCYC still holding above 60 pretty well

User Image Tickstocks Posted - 1 week ago

$BCYC Twits Stats Today's Change 15% + 🚀 https://t8sk.com/BCYC

User Image Sabini Posted - 1 week ago

Why is there no chart for $BCYC ? I want to see it going up

User Image StockTech7 Posted - 1 week ago

$BCYC Bicycle Strong

User Image Fox_Technicals Posted - 1 week ago

$BCYC 5 minute coil just above 60

User Image Fox_Technicals Posted - 1 week ago

That $BCYC 60 break was noice, lots of momo there

User Image Fox_Technicals Posted - 1 week ago

$BCYC back at 60 🚵‍♂️

User Image otcdynamics Posted - 2 weeks ago

$BCYC Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://www.otcdynamics.com/bcyc-bicycle-therapeutics-to-participate-in-upcoming-investor-conferences

User Image STCKPRO Posted - 2 weeks ago

$BCYC NEW ARTICLE : Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://www.stck.pro/news/BCYC/17854437

User Image Stonkmoon Posted - 2 weeks ago

$BCYC 2021-11-11 07:00 ET Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://stonkmoon.com/news/BCYC/9f4772584e8cf6ad9229da6058cac0d9

User Image cctranscripts Posted - 2 weeks ago

Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://conferencecalltranscripts.com/summary/?id=327417&pr=true $BCYC

User Image cctranscripts Posted - 2 weeks ago

Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://conferencecalltranscripts.com/summary/?id=327416&pr=true $BCYC

User Image fla Posted - 2 weeks ago

$BCYC [15s. delayed]: Issued Press Release on November 11, 07:00:00: Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://s.flashalert.me/gTjF0

User Image Quantisnow Posted - 2 weeks ago

$BCYC 📰 Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://quantisnow.com/insight/1994545?s=s 45 seconds delayed.

User Image Stock_Titan Posted - 2 weeks ago

$BCYC Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-participate-in-upcoming-investor-yogspp1qjn2x.html

User Image Newsfilter Posted - 2 weeks ago

$BCYC Bicycle Therapeutics to Participate in Upcoming Investor Conferences https://newsfilter.io/a/909a12170143a0d60f792e7ebad17f4f

User Image Fox_Technicals Posted - 2 weeks ago

$BCYC daily, 60 🚴🏻‍♂️

User Image Stonkmoon Posted - 2 weeks ago

$BCYC 2021-11-09 08:00 ET Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting https://stonkmoon.com/news/BCYC/a62a4d8fbba534b9e5730174854c3259

User Image cctranscripts Posted - 2 weeks ago

Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting https://conferencecalltranscripts.com/summary/?id=325022&pr=true $BCYC

User Image cctranscripts Posted - 2 weeks ago

Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting https://conferencecalltranscripts.com/summary/?id=325021&pr=true $BCYC

User Image fla Posted - 2 weeks ago

$BCYC [15s. delayed]: Issued Press Release on November 09, 08:00:00: Bicycle Therapeutics to Present Four Posters Highlighting Preclinical https://s.flashalert.me/uO1kJ

User Image Quantisnow Posted - 2 weeks ago

$BCYC 📰 Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting https://quantisnow.com/insight/1979836?s=s 45 seconds delayed.

User Image Newsfilter Posted - 2 weeks ago

$BCYC Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ Programs at the SITC 36th Annual Meeting https://newsfilter.io/a/bbff1306266de1f9a5821649b5fa38df

User Image Stock_Titan Posted - 2 weeks ago

$BCYC Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-present-four-posters-highlighting-rp7khstuukaq.html

Analyst Ratings
Canaccord Genuity Buy Jul 14, 21
Canaccord Genuity Buy Jul 12, 21
HC Wainwright & Co. Buy May 6, 21
JMP Securities Market Outperform Apr 19, 21
HC Wainwright & Co. Buy Jan 14, 21
Cantor Fitzgerald Overweight Oct 11, 20
Canaccord Genuity Buy Sep 9, 20
Oppenheimer Outperform Jun 11, 20
Roth Capital Buy Nov 13, 19
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lee Kevin Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 60.02 5,000 300,100 225,085 10/18/21
Lee Kevin Chief Executive Offi.. Chief Executive Officer Oct 11 Sell 54.22 5,000 271,100 230,085 10/13/21
Kalowski Lee President and CFO President and CFO Sep 03 Sell 40 10,000 400,000 09/03/21
Kalowski Lee President and CFO President and CFO Sep 03 Option 9.82 10,000 98,200 10,000 09/03/21